FDA批准可泰隆肺动脉高压药物Selexipag治疗成人肺动脉高压

2015-12-23 Mechront 译 MedSci原创

FDA批准爱可泰隆肺动脉高压药物 Selexipag (Uptravi)治疗成人肺动脉高压(PAH),这是一种一种罕见的慢性且逐步恶化的肺部疾病,会导致早逝或需要肺移植。 Selexipag是口服IP环前列腺素受体激动剂,放松血管壁肌层,舒张血管,降低肺部血液供应相关血管已升高的压力。对1156名成年PAH患者长达1.4年的研究评估了该药物的安全性和有效性。与对照组相比,Selexipag可有效减

FDA批准爱可泰隆肺动脉高压药物 Selexipag (Uptravi)治疗成人肺动脉高压(PAH),这是一种一种罕见的慢性且逐步恶化的肺部疾病,会导致早逝或需要肺移植。

Selexipag是口服IP环前列腺素受体激动剂,放松血管壁肌层,舒张血管,降低肺部血液供应相关血管已升高的压力。

对1156名成年PAH患者长达1.4年的研究评估了该药物的安全性和有效性。与对照组相比,Selexipag可有效减少PAH患者住院治疗,以及疾病恶化风险。不良反应包括头痛、腹泻、下巴疼痛、恶心、肌痛、呕吐、肢体疼痛和脸红等。

Selexipag为PAH患者提供了更多的选择。PAH患者使用Opsumit (macitentan)等基础治疗后,选择Selexipag可显著延缓疾病进展,效果优于疾病晚期阶段使用Veletri (epoprostenol) 治疗。公司预计Selexipag将于1月初在美国上市。目前欧洲、澳大利亚、加拿大、新西兰、南韩、瑞士、台湾正在审查药物Selexipag。

原始出处:

FDA Clears Selexipag for Pulmonary Arterial Hypertension


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1925141, encodeId=e17819251414d, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jun 13 23:49:00 CST 2016, time=2016-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839403, encodeId=cc8c18394030a, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Thu Nov 24 15:49:00 CST 2016, time=2016-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49374, encodeId=634e493e478, content=很值得好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 13:55:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47618, encodeId=a3094e618fc, content=比伟哥好吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Thu Dec 24 23:52:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47556, encodeId=dfcc4e55664, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Thu Dec 24 19:51:00 CST 2015, time=2015-12-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1925141, encodeId=e17819251414d, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jun 13 23:49:00 CST 2016, time=2016-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839403, encodeId=cc8c18394030a, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Thu Nov 24 15:49:00 CST 2016, time=2016-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49374, encodeId=634e493e478, content=很值得好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 13:55:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47618, encodeId=a3094e618fc, content=比伟哥好吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Thu Dec 24 23:52:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47556, encodeId=dfcc4e55664, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Thu Dec 24 19:51:00 CST 2015, time=2015-12-24, status=1, ipAttribution=)]
    2016-11-24 bugit
  3. [GetPortalCommentsPageByObjectIdResponse(id=1925141, encodeId=e17819251414d, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jun 13 23:49:00 CST 2016, time=2016-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839403, encodeId=cc8c18394030a, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Thu Nov 24 15:49:00 CST 2016, time=2016-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49374, encodeId=634e493e478, content=很值得好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 13:55:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47618, encodeId=a3094e618fc, content=比伟哥好吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Thu Dec 24 23:52:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47556, encodeId=dfcc4e55664, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Thu Dec 24 19:51:00 CST 2015, time=2015-12-24, status=1, ipAttribution=)]
    2015-12-27 忠诚向上

    很值得好学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1925141, encodeId=e17819251414d, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jun 13 23:49:00 CST 2016, time=2016-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839403, encodeId=cc8c18394030a, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Thu Nov 24 15:49:00 CST 2016, time=2016-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49374, encodeId=634e493e478, content=很值得好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 13:55:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47618, encodeId=a3094e618fc, content=比伟哥好吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Thu Dec 24 23:52:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47556, encodeId=dfcc4e55664, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Thu Dec 24 19:51:00 CST 2015, time=2015-12-24, status=1, ipAttribution=)]
    2015-12-24 忠诚向上

    比伟哥好吗?

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1925141, encodeId=e17819251414d, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jun 13 23:49:00 CST 2016, time=2016-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839403, encodeId=cc8c18394030a, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Thu Nov 24 15:49:00 CST 2016, time=2016-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49374, encodeId=634e493e478, content=很值得好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 13:55:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47618, encodeId=a3094e618fc, content=比伟哥好吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Thu Dec 24 23:52:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47556, encodeId=dfcc4e55664, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Thu Dec 24 19:51:00 CST 2015, time=2015-12-24, status=1, ipAttribution=)]
    2015-12-24 zhuzhuba1

    0

相关资讯

J Heart Lung Transplant:慢性血栓性肺动脉高压患者改善右室功能可选择球囊肺动脉成形术

背景:慢性血栓性肺动脉高压(CTEPH)致右心室(RV)适应性改变,常致RV衰竭及死亡。球囊肺动脉成形术(BPA)是肺动脉内膜切除术禁忌及肺动脉内膜切除术后残余肺动脉高压患者的一种治疗方法。研究者假设CTEPH患者BPA后RV重塑逆转机改善RV功能。方法:26个CTEPH患者(59 ± 12岁,11个男性患者),在进行前后4±2 BPA进行超声心动图,心肺运动实验,血液样本及右心导管的检查。根据当

Circulation:两机构联合推出儿科肺动脉高压临床治疗指南

2015年11月3日,美国心脏学会(The American Heart Association)与美国胸科学会( American Thoracic Society)在Circulation杂志上联合发布了第一版的评估和治疗儿科肺动脉高压( pulmonary hypertension , PH)的临床实践指南。两机构联合推出这份实践指南的目的基于在临床上,新生儿、幼儿的PH发病原因与治疗方式均

肺动脉高压特效药物万他维可能会退出中国市场,患者面临断药危机

2015年12月10日,一封由1400余名患者、医生、人大代表、病友组织、社会人士联名签署的公开信,以电子邮件的形式被发送到拜耳医药保健有限公司总部,希望其留下即将退出中国的肺动脉高压药“万他维”。 这一切源自半年前一封信。6月29日,中华慈善总会万他维患者援助项目办公室突然发出通知,终止万他维患者援助项目。通知中说,“由于捐赠方拜耳公司全球策略调整,万他维自2015年起将逐步退出中国市场”

ESC 2015:肺动脉高压指南亮点

1,新的治疗流程是新版指南最大亮点,并给出简明表格提示应当何时使用新近批准上市的药物。治疗策略基于患者的风险评估。2,指南基于近期研究证据对序贯和初始联合治疗做了推荐,并首次推荐“早期考虑行肺移植治疗”。3,针对CTEPH(慢性血栓栓塞性肺高压)也推荐了新的治疗流程,包括外科、药物和介入治疗。4,指南基于新证据更新了肺高压的临床和血流动力学分型,对儿科情况也进行了分类,并将肺血管抵抗(pulmon

荆志成教授:从肺动脉高压研究史,探ESC 2015新指南新意

中国医学科学院阜外医院荆志成教授 ESC上版肺动脉高压诊疗指南发布于2009年,今年ESC年会期间将发布新指南。荆志成教授指出,近20余年,学界在肺动脉高压发病机制、遗传学、诊断分类及治疗、新药研发等方面均取得显著进展,指南更新势在必行。2014年,相关专家向ESC提出更新指南,更新点包括流行病学数据、遗传学发现(2013年新发现基因突变引起平滑肌细胞钾通道开放障碍导致肺动脉高压)、发病机制

拜耳确认:肺动脉高压特效药物万他维并未撤出中国

近日,一则关于肺动脉高压治疗药物万他维,在中国的相关慈善援助项目即将结束,万他维将逐步退出中国市场的消息引发各方关注(肺动脉高压特效药物万他维可能会退出中国市场,患者面临断药危机)。舆论普遍担忧,万他维放弃中国市场,国内相关患者将面临断药,甚至在危急重症时会有性命之忧。

近日,记者从拜耳处获悉:万他维还将继续向中国患者提供。

拜耳表示,对患者援助项目中已入组患者的援助按原计划继续进行,直到该患者援助周期结束,拜耳正在寻找方案使该产品能够顺畅的供应。

· 2015-12-19

-->